Management of toxicities of immune checkpoint inhibitors L Spain, S Diem, J Larkin Cancer treatment reviews 44, 51-60, 2016 | 892 | 2016 |
Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal S Turajlic, H Xu, K Litchfield, A Rowan, T Chambers, JI Lopez, D Nicol, ... Cell 173 (3), 581-594. e12, 2018 | 711 | 2018 |
Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal S Turajlic, H Xu, K Litchfield, A Rowan, S Horswell, T Chambers, ... Cell 173 (3), 595-610. e11, 2018 | 543 | 2018 |
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 538 | 2018 |
Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal TJ Mitchell, S Turajlic, A Rowan, D Nicol, JHR Farmery, T O’Brien, ... Cell 173 (3), 611-623. e17, 2018 | 465 | 2018 |
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 413 | 2017 |
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma S Diem, B Kasenda, L Spain, J Martin-Liberal, R Marconcini, M Gore, ... British journal of cancer 114 (3), 256-261, 2016 | 309 | 2016 |
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ J Haanen, M Obeid, L Spain, F Carbonnel, Y Wang, C Robert, AR Lyon, ... Annals of Oncology 33 (12), 1217-1238, 2022 | 275 | 2022 |
Pervasive chromosomal instability and karyotype order in tumour evolution TBK Watkins, EL Lim, M Petkovic, S Elizalde, NJ Birkbak, GA Wilson, ... Nature 587 (7832), 126-132, 2020 | 271 | 2020 |
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature L Spain, G Walls, M Julve, K O’Meara, T Schmid, E Kalaitzaki, S Turajlic, ... Annals of Oncology 28 (2), 377-385, 2017 | 245 | 2017 |
Thyroid abnormalities following the use of cytotoxic T‐lymphocyte antigen‐4 and programmed death receptor protein‐1 inhibitors in the treatment of melanoma DL Morganstein, Z Lai, L Spain, S Diem, D Levine, C Mace, M Gore, ... Clinical endocrinology 86 (4), 614-620, 2017 | 204 | 2017 |
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma L Au, E Hatipoglu, MR de Massy, K Litchfield, G Beattie, A Rowan, ... Cancer cell 39 (11), 1497-1518. e11, 2021 | 151 | 2021 |
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma L Spain, R Higgins, K Gopalakrishnan, S Turajlic, M Gore, J Larkin Annals of Oncology 27 (6), 1135-1137, 2016 | 141 | 2016 |
Illness perception and health-related quality of life in multiple sclerosis L Spain, N Tubridy, T Kilpatrick, S Adams, A Holmes Acta Neurologica Scandinavica 116 (5), 293-299, 2008 | 121 | 2008 |
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection M Tio, R Rai, OM Ezeoke, JL McQuade, L Zimmer, C Khoo, JJ Park, ... European Journal of Cancer 104, 137-144, 2018 | 115 | 2018 |
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 100 | 2022 |
Representative sequencing: unbiased sampling of solid tumor tissue K Litchfield, S Stanislaw, L Spain, LL Gallegos, A Rowan, D Schnidrig, ... Cell reports 31 (5), 2020 | 59 | 2020 |
Selection of metastasis competent subclones in the tumour interior Y Zhao, X Fu, JI Lopez, A Rowan, L Au, A Fendler, S Hazell, H Xu, ... Nature ecology & evolution 5 (7), 1033-1045, 2021 | 58 | 2021 |
Hematological immune related adverse events after treatment with immune checkpoint inhibitors R Kramer, A Zaremba, A Moreira, S Ugurel, DB Johnson, JC Hassel, ... European Journal of Cancer 147, 170-181, 2021 | 49 | 2021 |
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis N Powell, H Ibraheim, T Raine, RA Speight, S Papa, O Brain, M Green, ... The Lancet Gastroenterology & Hepatology 5 (7), 679-697, 2020 | 44 | 2020 |